Quarterly report pursuant to Section 13 or 15(d)

Non-controlling Interest (Details)

v3.20.2
Non-controlling Interest (Details) - USD ($)
3 Months Ended 6 Months Ended
Sep. 05, 2018
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Noncontrolling Interest          
Related Party Transaction, Expenses from Transactions with Related Party $ 441,000        
Research and Development Expense   $ 1,603,000 $ 2,594,000 $ 3,238,000 $ 5,012,000
SYN Biomics          
Noncontrolling Interest          
Equity interest by parent   83.00%   83.00%  
Accumulated net loss attributable to the non-controlling interest   $ 2,900,000 2,900,000 $ 2,900,000 2,900,000
Cedarssinai Medical Center [Member]          
Noncontrolling Interest          
Number Of Common Stock To Be Issued 50,000 50,000   50,000  
Research and Development Expense   $ 25,000 $ 119,000 $ 92,000 $ 174,000
Fair Value Of Shares Issued $ 285,000        
Cedarssinai Medical Center [Member] | SYN Biomics          
Noncontrolling Interest          
Additional Number Of Common Stock To Be Issued 2,420,000        
Number Of Common Stock To Be Held By Related Party 7,480,000        
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners 17.00%